HRP20210112T1 - Režimi liječenja namijenjeni liječenju neurološke bolesti - Google Patents

Režimi liječenja namijenjeni liječenju neurološke bolesti Download PDF

Info

Publication number
HRP20210112T1
HRP20210112T1 HRP20210112TT HRP20210112T HRP20210112T1 HR P20210112 T1 HRP20210112 T1 HR P20210112T1 HR P20210112T T HRP20210112T T HR P20210112TT HR P20210112 T HRP20210112 T HR P20210112T HR P20210112 T1 HRP20210112 T1 HR P20210112T1
Authority
HR
Croatia
Prior art keywords
agent
peptide
intended
accordance
seq
Prior art date
Application number
HRP20210112TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Tymianski
Jonathan David Garman
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of HRP20210112T1 publication Critical patent/HRP20210112T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20210112TT 2009-06-10 2010-06-10 Režimi liječenja namijenjeni liječenju neurološke bolesti HRP20210112T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18598909P 2009-06-10 2009-06-10
EP10786859.8A EP2440230B1 (en) 2009-06-10 2010-06-10 Treatment regimes for treatment of neurological disease
PCT/US2010/038200 WO2010144721A2 (en) 2009-06-10 2010-06-10 Model systems and treatment regimes for treatment of neurological disease

Publications (1)

Publication Number Publication Date
HRP20210112T1 true HRP20210112T1 (hr) 2021-04-16

Family

ID=43309469

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210112TT HRP20210112T1 (hr) 2009-06-10 2010-06-10 Režimi liječenja namijenjeni liječenju neurološke bolesti

Country Status (14)

Country Link
US (2) US8940699B2 (cg-RX-API-DMAC7.html)
EP (2) EP3808366A1 (cg-RX-API-DMAC7.html)
JP (2) JP6005514B2 (cg-RX-API-DMAC7.html)
CN (1) CN102458441A (cg-RX-API-DMAC7.html)
AU (1) AU2010258664B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010718A2 (cg-RX-API-DMAC7.html)
CA (1) CA2765169C (cg-RX-API-DMAC7.html)
DK (1) DK2440230T3 (cg-RX-API-DMAC7.html)
ES (1) ES2847293T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210112T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053131T2 (cg-RX-API-DMAC7.html)
PL (1) PL2440230T3 (cg-RX-API-DMAC7.html)
PT (1) PT2440230T (cg-RX-API-DMAC7.html)
WO (1) WO2010144721A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
US9629892B2 (en) 2010-08-12 2017-04-25 Nono Inc. Treatment of penetrative injury to the brain
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
AU2012354072B2 (en) * 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2013204309A1 (en) * 2012-11-13 2014-05-29 Biodiem Limited Therapeutic Compounds and Uses Thereof
TR201905787T4 (tr) * 2012-11-28 2019-05-21 Nono Inc Liyofilize TAT-NR2B9C formülasyonu.
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
US20190134150A1 (en) * 2016-04-27 2019-05-09 Biocells (Beijing) Biotech Co., Ltd. Therapeutic methods for excitatory neurotoxicity-related injuries
US11229675B2 (en) 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯(北京)生物技术有限公司 一种缀合物及其应用
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
CN110799547B (zh) * 2017-07-05 2023-02-28 拜西欧斯(北京)生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
EP3693001A4 (en) 2017-09-30 2021-07-07 Biocells (Beijing) Biotech Co., Ltd. PEPTIDIC COMPOSITION ALLOWING THE TREATMENT OF INJURIES RELATED TO EXCITING NEUROTOXICITY
CN113121641B (zh) 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN113150065B (zh) 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114642402A (zh) * 2022-03-07 2022-06-21 翰博瑞强(上海)医药科技有限公司 一种用于预测药物对心脏毒性影响的方法及心电图设备
CN114469084B (zh) * 2022-04-02 2022-06-24 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
CA2505479A1 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
BRPI0409865A (pt) 2003-05-02 2006-05-16 Paion Deutschland Gmbh injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
CA2657665C (en) * 2006-07-11 2015-06-02 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2012354072B2 (en) 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia

Also Published As

Publication number Publication date
US8940699B2 (en) 2015-01-27
US20120269733A1 (en) 2012-10-25
WO2010144721A3 (en) 2011-04-21
AU2010258664B2 (en) 2015-05-28
HUE053131T2 (hu) 2021-06-28
CA2765169C (en) 2019-06-18
BRPI1010718A2 (pt) 2016-03-15
EP2440230A4 (en) 2014-05-28
EP2440230A2 (en) 2012-04-18
AU2010258664A1 (en) 2012-01-12
CA2765169A1 (en) 2010-12-16
DK2440230T3 (da) 2021-01-18
ES2847293T3 (es) 2021-08-02
JP2012530057A (ja) 2012-11-29
JP6220371B2 (ja) 2017-10-25
US20150202253A1 (en) 2015-07-23
US9610323B2 (en) 2017-04-04
JP2016041731A (ja) 2016-03-31
CN102458441A (zh) 2012-05-16
EP2440230B1 (en) 2020-11-11
PT2440230T (pt) 2021-02-03
WO2010144721A2 (en) 2010-12-16
PL2440230T3 (pl) 2021-06-14
EP3808366A1 (en) 2021-04-21
JP6005514B2 (ja) 2016-10-12

Similar Documents

Publication Publication Date Title
JP2012530057A5 (cg-RX-API-DMAC7.html)
Horowitz et al. Intra/extra-aneurysmal stent placement for management of complex and wide-necked-bifurcation aneurysms: eight cases using the waffle cone technique
Cheng et al. Endovascular treatment of radiation-induced petrous internal carotid artery aneurysm presenting with acute haemorrhage. A report of two cases
Sharma et al. Gd nanoparticulates: from magnetic resonance imaging to neutron capture therapy
Akgul et al. Y-stent-assisted coil embolization of wide-neck intracranial aneurysms: a single center experience
Dmytriw et al. Endovascular treatment of head and neck arteriovenous malformations
WO2007105217A3 (en) Aneurysm coil delivery system
JP2014520142A5 (cg-RX-API-DMAC7.html)
EP0352325A4 (de) Okklusionsmittel.
Mehanna et al. Endovascular treatment of sigmoid sinus aneurysm presenting as devastating pulsatile tinnitus: a case report and review of literature
Atanda et al. Contrast-induced acute kidney injury in interventional cardiology: emerging evidence and unifying mechanisms of protection by remote ischemic conditioning
De Beule et al. Transarterial embolization of peripheral arteriovenous malformations with ethylenevinyl alcohol copolymer-feasibility, technical outcomes, and clinical outcomes
JP2023511057A (ja) 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド
Babaker et al. Endovascular treatment of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia
Matsuda et al. Occlusion of the internal carotid artery by means of microcoils for preventing epistaxis caused by guttural pouch mycosis in horses
Ozaki et al. Endovascular Treatment of Spontaneous Isolated Dissecting Aneurysm of the Superior Mesenteric Artery Using Stent-Assisted Coil Embolization: T. Ozaki et al.
Xu et al. Efficacy of transarterial chemoembolization combined with radiofrequency ablation in treatment of hepatocellular carcinoma
Yuen et al. Endovascular treatment of a pseudoaneurysm of a recipient external carotid artery following radiation and free tissue transfer
Lesley et al. Balloon test occlusion and endosurgical parent artery sacrifice for the evaluation and management of complex intracranial aneurysmal disease
Kim et al. Combined surgical and endovascular treatment of a recurrent A3–A3 junction aneurysm unsuitable for standalone clip ligation or coil occlusion
Garg et al. Intra-aneurysmal glue embolisation of a giant pulmonary artery pseudoaneurysm after left upper lobe lobectomy: case report
Choi et al. Percutaneous transabdominal approach for the treatment of endoleaks after endovascular repair of infrarenal abdominal aortic aneurysm
Chen et al. Repeated massive epistaxis after re‑irradiation in recurrent nasopharyngeal carcinoma
Kusaka et al. Combined Use of TruFill DCS Detachable Coil System and Guglielmi Detachable Coil for Embolization of Meningioma Fed by Branches of the Cavernous Internal Carotid Artery—Technical Case Report—
Namikawa et al. Gastric ulcer bleeding from a variant left gastric artery accompanied by congenital absence of the splenic artery successfully treated with coil embolization: a case report and review of the literature.